Core Viewpoint - Bumble Inc. reported fourth-quarter results that exceeded revenue expectations, leading to a significant increase in share price despite a decline in user numbers [1] Financial Performance - The company posted a net loss of $4.06 per share for the fourth quarter, a decline from earnings of $0.04 per share in the same period last year, primarily due to $630.5 million in non-cash impairment charges [1] - Revenue for the fourth quarter declined 14.3% year over year to $224.2 million, surpassing the analyst consensus estimate of $221.68 million [2] - Total revenue for the full year 2025 fell 9.9% to $965.7 million, with Bumble App revenue declining 14.8% to $181.0 million in the fourth quarter [3] User Metrics - Total paying users dropped 20.5% to 3.3 million, while average revenue per paying user increased by 7.9% to $22.20 [2] - Revenue from Badoo App and Other segments decreased by 12.4% to $43.2 million [3] Future Outlook - For the first quarter of 2026, Bumble forecasts revenue between $209 million and $213 million, with an adjusted EBITDA projection of $76 million to $80 million [2]

Core Insights - UiPath reported quarterly results that exceeded analyst expectations for both earnings and revenue, but shares fell over 5% intra-day despite positive guidance for fiscal 2027 [1] Financial Performance - The company reported adjusted earnings of $0.30 per share on revenue of $481.11 million for fiscal fourth quarter 2026, surpassing analyst expectations of $0.26 per share on revenue of $464.88 million [1] - UiPath's annualized renewal run-rate (ARR) reached $1.853 billion as of January 31, 2026, marking an 11% year-over-year increase [2] - Net-new ARR increased by 20% on a reported basis but saw a decline of 5% when adjusted for constant currency [2] AI Product Performance - Management disclosed that AI-related products generated $200 million in ARR, which includes AI agents, the Maestro orchestration platform, and Intelligent Document Processing solutions [2] Future Guidance - For fiscal first-quarter 2027, UiPath expects revenue to be between $395 million and $400 million [3] - The company projected full fiscal year 2027 revenue between $1.754 billion and $1.759 billion, exceeding the analyst consensus estimate of $1.74 billion [3]

Core Viewpoint - Tilly's, Inc. reported a strong fourth-quarter earnings beat, marking its first profitable fourth quarter since fiscal 2021, with shares surging over 50% intra-day following the announcement [1] Financial Performance - The company posted adjusted earnings of $0.10 per share for the quarter ended January 31, 2026, significantly outperforming analyst expectations for a loss of $0.32 per share [1] - Revenue reached $155.1 million, increasing 5.3% year over year and exceeding the consensus estimate of $146.1 million [2] - Comparable store sales climbed 10.1%, marking the seventh consecutive month of positive comparable sales growth [2] - Gross profit margin expanded to 33.2%, up from 26.0% in the prior-year period, reflecting a 470-basis-point increase in product margins due to higher initial markups and reduced markdown activity [3] - Selling, general and administrative expenses declined by $3.5 million to $48.9 million, primarily due to lower store payroll costs [3] Future Guidance - For the first quarter of fiscal 2026, Tilly's issued guidance that exceeded expectations, forecasting revenue between $119 million and $125 million, with a midpoint of $122 million well above the analyst consensus estimate of $106.5 million [4] - The outlook implies comparable sales growth between 16% and 22% [4] - Tilly's expects a net loss of $0.27 to $0.34 per share in the quarter, representing an improvement from the $0.74 loss reported in the same period last year [5]

Core Viewpoint - Hurco Companies, Inc. reported a net loss for the first quarter of fiscal 2026, with significant declines in sales and profitability metrics, while new orders showed a slight increase, indicating mixed performance amid challenging market conditions [2][6][10]. Financial Performance - Hurco reported a net loss of $3.5 million, or $0.54 per diluted share, for Q1 fiscal 2026, compared to a net loss of $4.3 million, or $0.67 per diluted share, in the same quarter last year [2]. - Sales and service fees decreased by 7.6% year over year to $42.9 million from $46.4 million [2]. - Gross profit was $7.9 million, down 4.2% from $8.3 million a year earlier, but gross margin improved to 19% from 18% [7]. Regional Sales Performance - Sales fell by 8% in the Americas to $16.6 million, decreased by 5% in Europe to $20.5 million, and dropped by 15% in the Asia Pacific region to $5.7 million [3]. - Computerized machine tool sales, the largest revenue contributor, declined by 11.3% year over year to $33.5 million from $37.8 million [4]. Segment and Product Performance - Sales of computer control systems and software decreased by 31.1% year over year to $0.5 million from $0.7 million [5]. - Service parts revenue rose by 17% to $6.9 million from $5.9 million, while service fees declined by 3.8% to $2 million from $2.1 million [5]. Orders and Demand - New orders totaled $41.9 million, up 5% from $40.1 million in the prior-year quarter [6]. - Orders in the Americas increased by 18% to $17.3 million, while European orders declined by 2% to $18.9 million, and Asia Pacific orders fell by 6% to $5.7 million [6]. Cost Management and Financial Flexibility - Selling, general and administrative expenses rose by 6.9% to $11.1 million, representing 26% of sales compared to 22% in the prior-year quarter [8]. - The company has implemented cost-reduction initiatives and suspended its quarterly dividend to preserve cash [11]. Liquidity and Capital Resources - Hurco ended the quarter with $48 million in cash and cash equivalents, slightly down from $48.7 million at the end of fiscal 2025 [12]. - Capital expenditures during the quarter were approximately $0.6 million, primarily for software development and facility improvements [13]. Credit Facilities - Hurco entered into a new credit agreement with Bank of America providing a secured revolving credit and letter-of-credit facility of up to $20 million [14][17]. Management Commentary and Guidance - Management noted improved order activity in the U.S. despite higher tariffs and indicated that the uptick in U.S. orders could signal early signs of recovery in global machine tool markets [10]. - The company did not issue formal financial guidance for the remainder of fiscal 2026, citing uncertain demand conditions [15][16].

Core Insights - Dick's Sporting Goods reported fourth-quarter results that exceeded analyst expectations, with adjusted earnings per share of $3.45, surpassing the consensus estimate of $3.03 by $0.42 [1] - Revenue for the quarter reached $6.23 billion, exceeding the forecast of $6.08 billion and representing a 59.9% increase from $3.89 billion in the prior-year quarter, largely driven by the acquisition of Foot Locker [1] Fiscal 2026 Guidance - The company forecasted adjusted earnings per share for fiscal 2026 between $13.50 and $14.50, compared to the analyst consensus estimate of $12.77, with the midpoint of $14.00 representing a 9.6% premium to expectations [2] - Revenue for fiscal 2026 is expected to range from $22.1 billion to $22.4 billion, with the midpoint of $22.25 billion being approximately 2.1% above the consensus estimate of $21.8 billion [2] - Following the announcement, shares rose by 3.8% [2] Fiscal 2025 Performance - For fiscal 2025, Dick's recorded comparable sales growth of 4.5% and adjusted earnings per share of $14.58, an increase from $14.05 in the previous year [3] - The company opened 16 House of Sport locations and 15 Dick's Field House stores during 2025, with plans to launch about 14 additional House of Sport and 22 Dick's Field House locations in 2026 [3] Dividend and Sales Growth Expectations - The board approved a 3% dividend increase to an annualized payout of $5.00 per share [4] - Dick's expects comparable sales growth of 2.0% to 4.0% in fiscal 2026 for its core business, and pro forma comparable sales growth of 1.0% to 3.0% for the Foot Locker segment [4]

Core Insights - Relmada Therapeutics (RLMD) shares surged 42% in one week following the announcement of positive 12-month interim data from a mid-stage study of NDV-01 for high-risk non-muscle invasive bladder cancer (NMIBC) [2][6] Study Results - The phase II study of NDV-01 demonstrated a 12-month complete response (CR) rate of 76%, with CR rates of 87% at three months, 86% at six months, and 85% at nine months [3][6] - In the BCG-unresponsive subgroup, NDV-01 achieved a 12-month CR rate of 80%, with no patients progressing to muscle-invasive disease or requiring radical cystectomy [4][6] Safety Profile - NDV-01 exhibited a favorable safety profile, with treatment-related adverse events mostly mild to moderate, and no discontinuations due to adverse events reported [5][6] Future Development Plans - Relmada Therapeutics plans to advance NDV-01 into the phase III RESCUE registrational program targeting both second-line BCG-unresponsive and adjuvant intermediate-risk NMIBC settings, with program initiation expected in mid-2026 [4][7][11] - The first pathway will evaluate NDV-01 as an adjuvant therapy for intermediate-risk NMIBC patients, with disease-free survival as the primary endpoint [8] - The second pathway will focus on a single-arm study in second-line BCG-unresponsive NMIBC patients, with the primary endpoint being the CR rate at any time [9][11]

Core Viewpoint - Lowey Dannenberg P.C. is investigating Fulgent Genetics, Inc. for potential violations of federal securities laws following the company's financial results for 2025, which fell short of expectations [1][2]. Financial Performance - Fulgent reported full year 2025 revenue of approximately $322.7 million, which was slightly below the updated guidance previously provided [2]. - The company also indicated a sequential decline in revenue for the fourth quarter [2]. Legal Investigation - The investigation by Lowey Dannenberg focuses on potential corporate fraud and malfeasance that may have led to financial losses for investors [1][4].

Core Insights - Merck & Co., Inc. is a global healthcare company facing competition from major pharmaceutical companies like Pfizer and Johnson & Johnson [1] - Mohit Bansal from Wells Fargo has set a price target of $150 for MRK, indicating a potential increase of 29.07% from its current price of $116.22 [1][6] Sales Performance - Gardasil vaccine sales dropped by 39% year over year in 2025, totaling $5.2 billion, primarily due to weak demand in China [2][6] - The decline in Gardasil sales is compounded by reduced demand in Japan and other vaccines, with management not expecting a recovery in 2026 [3] Stock Performance - MRK's current stock price is $115.48, reflecting a slight decrease of 0.63% from the previous day, with a market capitalization of approximately $285.5 billion [4][6] - Over the past year, MRK has experienced stock price volatility, with a high of $125.14 and a low of $73.31 [4] Market Activity - Today's trading volume for MRK is 687,521 shares, indicating investor interest and market activity [5]

There is an ETF that is standing out in the energy landscape in positive terms, with a six-month return above +30%, directly linked to the energy shock following the opening of the conflict in Iran: we are talking about the VanEck Oil Refiners ETF (Financial Serenity is a financial analysis and quantitative research column with a particular focus on the asset management sector. It is actively managed by Tommaso Scarpellini, a seasoned financial researcher and data analyst with proven experience in banking a ...

Core Viewpoint - G-III Apparel Group, Ltd. reported disappointing fourth-quarter results and provided weak guidance for fiscal 2027, leading to a significant drop in share price [1] Financial Performance - The company reported an adjusted loss of $0.30 per share for the quarter ended January 31, 2026, which was below analyst expectations [2] - Revenue for the quarter decreased by 8.1% to $771.5 million from $839.5 million in the same period last year [2] - For fiscal 2026, net sales fell by 7% to $2.96 billion compared to $3.18 billion in the previous year, with adjusted earnings per share of $2.61 [3] Bad-Debt Impact - The quarter included $17.5 million in bad-debt expenses primarily related to the Saks Global bankruptcy, which impacted earnings by approximately $0.32 per share after tax [2] - The revenue decline was attributed to a loss of $254 million in sales from PVH brands, although key owned brands experienced mid-single-digit growth [3] Future Guidance - For fiscal 2027, G-III expects net sales to be approximately $2.71 billion, down from $2.96 billion in fiscal 2026, reflecting a loss of $470 million in revenue due to the exit from Calvin Klein and Tommy Hilfiger licensing agreements [4] - The company forecasts adjusted earnings per share between $2.00 and $2.10, with a midpoint of $2.05 [4] - For the first quarter, G-III anticipates revenue of roughly $530 million compared to $583.6 million in the prior year and projects an adjusted loss of $0.30 to $0.40 per share [4]